1.	Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
2.	Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0307, NCT00619879
3.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
4.	Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 4 to 21 Sponsor: NCI Protocol IDs: NCI-01-C-0125F, NCT00020592
5.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
6.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
7.	Reduced Intensity Transplant Using Extracorporeal Photopheresis Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and under Sponsor: Pharmaceutical / Industry Protocol IDs: ECP RIT, NCT00179790
8.	Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 2005-0508, NCT00402558
9.	Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 55 Sponsor: NCI, Other Protocol IDs: 06-125, MSKCC-06125, NCT00423514
10.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
11.	Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 6 montha to 70 Sponsor: Other Protocol IDs: J1055, NA_00039823, NCT01203722
12.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
13.	Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2011-0254, NCT01460498
14.	Improving Blood Stem Cell Collection and Transplant Procedures Phase: Phase II, Phase I Type: Treatment Status: Active Age: 3 to 79 Sponsor: NHLBI Protocol IDs: 120028, 12-H-0028, NCT01517035
15.	Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Phase: Phase II, Phase I Type: Treatment Status: Active Age: 13 to 60 Sponsor: NCI, Other Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
16.	Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Phase: Phase II Type: Treatment Status: Active Age: 8 to 80 Sponsor: NHLBI Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
17.	Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
18.	Fludarabine Phosphate and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib Phase: Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: NCI, Other Protocol IDs: 1581.00, NCI-2010-00131, P01CA078902, P01CA018029, FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738
19.	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: PSCI-2003-232, NCT00084695
20.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
21.	Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer Phase: Phase II Type: Treatment Status: Active Age: 45 and under Sponsor: Other Protocol IDs: 2005LS043, UMN-MT2005-10, UMN-0507M71475, UMN-2005LS043, UMN-BMT-MT2005-10, NCT00309842
22.	Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy Phase: Phase II Type: Treatment Status: Active Age: Under 70 Sponsor: Other Protocol IDs: 2001LS058, UMN-MT2001-10, 0108M06725, UMN-2001LS058, NCT00303719
23.	Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) Phase: Phase II Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: BMT 0300 Mini, NCT00179764
24.	Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By an Umbilical Cord Blood Transplant, Sirolimus, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer Phase: Phase II Type: Treatment Status: Active Age: Under 70 Sponsor: Other Protocol IDs: 2005LS036, UMN-MT-2005-02, UMN-0507M70121, UMN-2005LS036, NCT00305682
25.	Cyclophosphamide, Fludarabine, Total-Body Irradiation, and Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer or Other Disease Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 50 Sponsor: Other Protocol IDs: CDR0000502363, MSKCC-06014, NCT00388102